Clariant TEA extension request
This article was originally published in The Rose Sheet
Executive Summary
Piroctone olamine manufacturer Clariant seeks 90-day extension to "assemble a comprehensive submission" to FDA on the safety and efficacy of the anti-dandruff ingredient. Firm requests original deadline of May 18 be pushed back to Aug. 16, Washington, D.C. law firm Keller and Heckman says in letter to FDA filed April 16 on behalf of Clariant. Agency issued a call for safety and efficacy data on piroctone olamine as a single active dandruff control ingredient in February to determine if it is eligible for monograph status (1"The Rose Sheet" Feb. 23, 2004, p. 10). Review follows submission of a time and extent application by Clariant...
You may also be interested in...
Clariant TEA extension
FDA grants piroctone olamine manufacturer's request for extension of public comment period for anti-dandruff ingredient safety and efficacy review to August 16. In a May 19 Federal Register 1notice, the agency said it "considers an extension of time for submission of data, information and general comments concerning the safety and effectiveness of piroctone olamine to be in the public interest." Clariant had requested the 90-day extension to assemble a "more comprehensive" submission for the ingredient in an April 16 letter to FDA (2"The Rose Sheet" May 10, 2004, In Brief)...
FDA To Review Piroctone Olamine For OTC Dandruff Monograph Status
FDA is seeking safety and efficacy data on piroctone olamine for use as a single active ingredient in dandruff control products, the agency announced in a Federal Register 1notice Feb. 18
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.